Literature DB >> 22128346

Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.

S Stevens Negus1, Robert O'Connell, Ember Morrissey, Kejun Cheng, Kenner C Rice.   

Abstract

κ opioid receptor agonists that do not readily cross the blood-brain barrier are peripherally restricted and distribute poorly to the central nervous system after systemic administration. Peripherally restricted κ agonists have promise as candidate analgesics, because they may produce antinociception mediated by peripheral κ receptors more potently than they produce undesirable sedative and psychotomimetic effects mediated by central κ receptors. The present study used assays of pain-related stimulation and depression of behavior in rats to compare effects of 1) two peripherally restricted κ agonists [the tetrapeptide D-Phe-D-Phe-D-Ile-D-Arg-NH(2) (ffir) and the nonpeptidic compound ((R,S)-N-[2-(N-methyl-3,4-dichlorophenylacetamido)-2-(3-carboxyphenyl)-ethyl]pyrrolidine hydrochloride (ICI204448)], 2) a centrally penetrating κ agonist (salvinorin A), and 3) several reference drugs, including a nonsteroidal anti-inflammatory drug (NSAID; ketoprofen). Intraperitoneal injection of dilute lactic acid served as a noxious stimulus to stimulate a stretching response and depress intracranial self-stimulation (ICSS) maintained by the delivery of electrical brain stimulation to the medial forebrain bundle. Acid-stimulated stretching was blocked by ketoprofen, the peripherally restricted κ agonists, and salvinorin A. However, acid-induced depression of ICSS was blocked only by ketoprofen. The peripherally restricted κ agonists had little effect, and salvinorin A exacerbated acid-induced depression of ICSS. These results suggest that peripherally restricted κ agonists may be safer than centrally penetrating κ agonists but less efficacious than NSAIDS or μ opioid receptor agonists to block pain-related depression of behavior; however, the peripheral selectivity of ffir and ICI204448 is limited, and future studies with κ agonists capable of greater peripheral selectivity are warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128346      PMCID: PMC3286312          DOI: 10.1124/jpet.111.186783

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia.

Authors:  S Stevens Negus; Edward J Bilsky; Gail Pereira Do Carmo; Glenn W Stevenson
Journal:  Methods Mol Biol       Date:  2010

2.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.

Authors:  Todd W Vanderah; Tally Largent-Milnes; Josephine Lai; Frank Porreca; Richard A Houghten; Frédérique Menzaghi; Kazimierz Wisniewski; Jacek Stalewski; Javier Sueiras-Diaz; Robert Galyean; Claudio Schteingart; Jean-Louis Junien; Jerzy Trojnar; Pierre J-M Rivière
Journal:  Eur J Pharmacol       Date:  2008-01-24       Impact factor: 4.432

3.  Ketoprofen produces modality-specific inhibition of pain behaviors in rats after plantar incision.

Authors:  Christina M Spofford; Hazem Ashmawi; Alberto Subieta; Fatima Buevich; Arikha Moses; Max Baker; Timothy J Brennan
Journal:  Anesth Analg       Date:  2009-12       Impact factor: 5.108

4.  Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior.

Authors:  Gail Pereira Do Carmo; Glenn W Stevenson; William A Carlezon; S Stevens Negus
Journal:  Pain       Date:  2009-05-10       Impact factor: 6.961

5.  Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Authors:  Lars Arendt-Nielsen; Anne E Olesen; Camilla Staahl; Frédérique Menzaghi; Sherron Kell; Gilbert Y Wong; Asbjørn M Drewes
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

6.  Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.

Authors:  A W Mangel; J D Bornstein; L R Hamm; J Buda; J Wang; W Irish; D Urso
Journal:  Aliment Pharmacol Ther       Date:  2008-05-07       Impact factor: 8.171

7.  Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.

Authors:  Lawrence A Szarka; Michael Camilleri; Duane Burton; Jean C Fox; Sanna McKinzie; Timothy Stanislav; Julie Simonson; Nancy Sullivan; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-27       Impact factor: 11.382

8.  Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats.

Authors:  Elena H Chartoff; David Potter; Diane Damez-Werno; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

Review 9.  Animal models of pain: progress and challenges.

Authors:  Jeffrey S Mogil
Journal:  Nat Rev Neurosci       Date:  2009-03-04       Impact factor: 34.870

10.  Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice.

Authors:  Glenn W Stevenson; Jim Cormier; Hannah Mercer; Chloe Adams; Catherine Dunbar; S Stevens Negus; Edward J Bilsky
Journal:  Life Sci       Date:  2009-06-24       Impact factor: 5.037

View more
  33 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

3.  The effect of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats.

Authors:  Clayton T Bauer; Matthew L Banks; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-01-10       Impact factor: 4.530

4.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

Review 5.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

6.  Effects of peripheral and spinal κ-opioid receptor stimulation on the exercise pressor reflex in decerebrate rats.

Authors:  Steven W Copp; Audrey J Stone; Katsuya Yamauchi; Marc P Kaufman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-11       Impact factor: 3.619

7.  Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.

Authors:  Tarsis F Brust; Jenny Morgenweck; Susy A Kim; Jamie H Rose; Jason L Locke; Cullen L Schmid; Lei Zhou; Edward L Stahl; Michael D Cameron; Sarah M Scarry; Jeffrey Aubé; Sara R Jones; Thomas J Martin; Laura M Bohn
Journal:  Sci Signal       Date:  2016-11-29       Impact factor: 8.192

8.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.